In 2013, experts reached a consensus to adopt the term C3 glomerulopathy (C3G) to define a group of rare kidney diseases driven by dysregulation of the alternative complement pathway, mediated by geneticRead More…
Features of the Three Complement Activation Pathways
There are three complement activation pathways in the complement system, that is, the classical pathway, the alternative pathway, and the lectin pathway. The three pathways have different origins, but they cross eachRead More…
Pegcetacoplan, a Peptide Drug Targeting Complement C3, Helps in the Treatment of Ophthalmic Diseases and Rare Diseases
The complement system, also known as the complement cascade, is a crucial component of both the innate and the adaptive immune systems, which can assist or supplement antibodies and phagocytes to clearRead More…
FDA Approved the First Long-acting Complement C5 Inhibitor for the Treatment of Myasthenia Gravis!
On April 28, AstraZeneca released news that its subsidiary Alexion’s new drug Ultomiris (Ravulizumab) was approved by the FDA for the treatment of anti-acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG) adultRead More…
Aptamer Drug Conjugate (ApDC): Advantages and Applications
Targeted therapy is the strategies employed by of most current tumor drugs, but in fact many of them have poor selectivity and certain off-target toxicity. Correspondingly, an approach that becomes increasingly prominentRead More…
Atypical Hemolytic Uremic Syndrome and the Complement System
According to statistics, the prevalence of atypical hemolytic uremic syndrome (aHUS) is about seven in one million. The majority of aHUS have complement-related factor gene mutations, and the etiology of about 6%Read More…
C5AR1: A Potential Target in The Complement System for COVID-19 Drug Development
With the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) still ongoing, the prevention and treatment of COVID-19 has become a research focus inRead More…
FDA Approved Complement C1s Antibody: Sanofi Sutimlimab
On February 4, 2022, Sanofi announced that its complement C1s antibody Sutimlimab was approved by the FDA for the treatment of cold agglutinin disease (CAD) under the trade name Enjaymo. Sutimlimab isRead More…